ALSO NOTED: FDA, Researchers butt heads over genetic screening;FDA approves Omrix's Evithrom;

> Perhaps this is a taste of genetic-screening battles to come: researchers at the University of North Carolina are questioning the FDA's genetic screening guidelines for the cancer drug Camptosar. The agency recommends that patients be checked for genes that make them susceptible to harmful side effects, but in a study published in the Journal of the National Cancer Institute, the researchers found that the troublesome genes only increase the risk of side effects at high doses of the drug. Report

> Omrix Biopharmaceuticals got a boost yesterday with the FDA's approval of Evithrom, a protein used to control bleeding during surgery. It's the first human thrombin product approved since 1954. The product will be distributed by Johnson & Johnson. Release

> The FDA has accepted Merck's new drug application for its cholesterol drug Cordaptive, a form of niacin designed to raise levels of HDL, or "good" cholesterol. The company expects regulatory action on the remedy by second quarter 2008. Release

> The oral form of Pharmion's blood disorder remedy Azacitidine stepped onto the FDA fast track today. The drug is already approved in its injectible form, sold as Vidaza. Release

And Finally... Democrat John Edwards proposed raising the cancer stakes first. Now, GOP candidates Sam Brownback, Mike Huckabee, and Mitt Romney are pitching in with their own proposals to boost federal spending on cancer research and prevention. Report

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

North Korean hackers were accused of posing as corporate recruiters in a scheme to breach AstraZeneca's computer systems and steal COVID-19 research.

The FDA has delayed its review of Revance's frown-line injection candidate after it failed to inspect a key manufacturing facility on time.

McKinsey & Company helped guide Purdue's strategy for years and pitched the idea of rebates to distributors for overdoses, according to the NYT.